Tumor markers at the time of recurrence in patients with germ cell tumors

α‐fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) closely follow the course of germ cell tumors (GCTs) and are widely used for diagnosis, prognosis, and follow‐up purposes. The objective of this study was to assess the concordance of tumor markers at the time of diagnosis and recurrence.

[1]  C. Gerharz,et al.  Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro , 2000, Cancer.

[2]  J. Reis-Filho,et al.  Evaluation of cell proliferation, epidermal growth factor receptor, and bcl‐2 immunoexpression as prognostic factors for patients with world health organization grade 2 oligodendroglioma , 2000, Cancer.

[3]  David Fortin,et al.  Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood‐brain barrier for the treatment of patients with malignant brain tumors , 2000, Cancer.

[4]  Z. Wszolek,et al.  Predominance of brain tumors in an extended Li‐Fraumeni (SBLA) kindred, including a case of Sturge‐Weber syndrome , 2000, Cancer.

[5]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[6]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Wilmanns,et al.  Prognosis after salvage treatment for unselected male patients with germ cell tumours. , 1995, British Journal of Cancer.

[8]  L. Weissbach,et al.  HCG-positive seminoma. , 1993, European urology.

[9]  F. Freiha,et al.  Serum markers in germ cell neoplasms. , 1991, Hematology/Oncology Clinics of North America.

[10]  L. Einhorn.  Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Paus,et al.  Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Seckl,et al.  Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. , 1990, British Journal of Cancer.

[14]  A. Horwich,et al.  Management of patients with non-seminomatous germ cell tumours stage I. , 1990, Progress in clinical and biological research.

[15]  S. Fosså,et al.  Serum lactate dehydrogenase and human choriogonadotrophin in seminoma. , 1989, British journal of urology.

[16]  V. Harvey,et al.  Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Husband,et al.  Stage I nonseminomatous germ cell tumors of the testis: radiologic follow-up after orchidectomy. , 1987, Radiology.

[18]  D. Longo,et al.  Use of serum tumor markers in cancer diagnosis and management. , 1987, Seminars in oncology.

[19]  W. Shipley,et al.  Pure seminoma of the testis: the results of radiation therapy in patients with elevated human chorionic gonadotropin titers. , 1985, The Journal of urology.

[20]  N. Geller,et al.  Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. , 1983, The American journal of medicine.

[21]  A. Barrett,et al.  The management of metastatic seminoma testis , 1982, Cancer.

[22]  A. Neville,et al.  Elevated serum alphafetoprotein and seminoma clinical evidence for a histologic continuum? , 1982, Cancer.

[23]  R. Weichselbaum,et al.  The significance of positive chorionic gonadotropins in apparently pure seminoma of the testis. , 1979, International journal of radiation oncology, biology, physics.

[24]  T. Waldmann,et al.  Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders. , 1978, Surgery, gynecology & obstetrics.

[25]  T. Waldmann,et al.  Cellular localization of alpha‐fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers , 1977 .

[26]  T. Waldmann,et al.  Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. , 1976, The New England journal of medicine.

[27]  T. Waldmann,et al.  The use of a radioimmunoassay for alpha‐fetoprotein in the diagnosis of malignancy , 1974, Cancer.

[28]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .